Related Experiment Video

Updated: Jan 15, 2026

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

18.6K

RALGEF inhibitors suppress RAS-driven pancreatic cancer and metastasis

Howard Donninger1, Rachel Ferrill2, Becca von Baby2

  • 1Department of Medicine, University of Louisville, Louisville, Kentucky, USA.

The Journal of Biological Chemistry
|October 10, 2025
PubMed

Insights

Researchers developed the first small molecule inhibitor targeting pan-Ras-like (RAL) small GTPase exchange factors (RALGEF). This compound suppresses RAS/RAL signaling and demonstrates antitumor effects in preclinical models, offering a new therapeutic avenue for RAS-driven cancers.

Area of Science:

  • Oncology
  • Molecular Biology
  • Drug Discovery

Background:

  • RAS oncoproteins are frequently activated in cancer, but direct inhibitors face challenges like resistance.
  • Targeting RAS downstream effectors (RAF, PI-3 kinase, RALGEF) is an alternative strategy.
  • Existing inhibitors for RAF and PI-3 kinase have limited clinical efficacy; RALGEF inhibitors are underexplored despite their importance in RAS-driven transformation.

Purpose of the Study:

  • To develop and characterize the first small molecule inhibitor targeting pan-RALGEF.
  • To evaluate the inhibitor's specificity for RAS/RAL signaling.
  • To assess the compound's antitumor efficacy in preclinical cancer models.

Main Methods:

  • Development of a novel small molecule pan-RALGEF inhibitor.
  • Assessment of inhibitor specificity against RAS/RAL signaling pathways.
  • Evaluation of antitumor activity in xenograft and patient-derived xenograft (PDX) models.

Main Results:

  • The novel compound functions as a specific inhibitor of pan-RALGEF.
  • The inhibitor effectively suppresses RAS/RAL signaling.
  • Significant antitumor effects were observed in preclinical xenograft models, including a PDX model.

Conclusions:

  • This first-in-class pan-RALGEF inhibitor shows promise for targeting RAS-driven tumors.
  • The compound demonstrates specific suppression of RAS/RAL signaling and antitumor activity.
  • This approach may lead to more effective therapies for various RAS-driven cancers.
Keywords:
AktRALGDS inhibitorRAS proteincell signalingmitogen-activated protein kinase (MAPK)pancreatic cancer

More Related Videos

Identification of EGFR and RAS Inhibitors using Caenorhabditis elegans08:12

Identification of EGFR and RAS Inhibitors using Caenorhabditis elegans

Published on: October 5, 2020

3.3K
Identification and Characterization of Metastatic Factors by Gene Transfer into the Novel RIP-Tag; RIP-tva Murine Model09:03

Identification and Characterization of Metastatic Factors by Gene Transfer into the Novel RIP-Tag; RIP-tva Murine Model

Published on: October 16, 2017

9.1K

Related Concept Videos

The Ras Gene02:38

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...
7.0K
Small GTPases - Ras and Rho01:24

Small GTPases - Ras and Rho

Ras and Rho are small monomeric GTPases that act downstream of receptor tyrosine kinase (RTK) and regulate various cellular processes. These GTPases switch between active and inactive states by binding to guanine nucleotides.
Three regulatory proteins control their activity:
5.2K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.6K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.5K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.1K